Friedl-Naderer Johanna 4

What Happened

• Johanna Friedl‑Naderer, Chief Commercial Officer of Dyne Therapeutics (DYN), received equity awards on February 12, 2026: 60,000 restricted stock units (RSUs) and a 90,000‑share derivative award (an option). The filing reports $0.00 per share for these grants (i.e., they were awarded, not purchased).

Key Details

• Transaction date: February 12, 2026; Form 4 filed February 17, 2026 (timely filing).
• Awards: 60,000 RSUs (each converts to one share upon vesting) and 90,000 shares of a derivative option granted the same day.
• Vesting: RSUs vest in equal quarterly installments over four years beginning May 12, 2026. The option vests in equal monthly installments over four years through February 12, 2030.
• Shares owned after the transaction: not specified in the excerpt; footnote notes 132,152 unvested RSUs are included in reported holdings.
• No sale or cash exercise reported; this is a compensation grant (not a market purchase or sale).

Context

• These are standard equity compensation awards to an executive and do not represent an open‑market purchase or sale. RSUs convert to shares only as they vest; the option grants give the right to acquire shares over time per the stated vesting schedule. Such grants are routine for executive compensation and should be interpreted as compensation, not a direct market sentiment signal.